Urine Haptoglobin Can Predict Kidney Damage in T2DM

Share this content:
Urine Haptoglobin Can Predict Kidney Damage in T2DM
Urine Haptoglobin Can Predict Kidney Damage in T2DM

WEDNESDAY, Dec. 7, 2016 (HealthDay News) -- Urine haptoglobin is a novel biomarker for predicting kidney damage in patients with type 2 diabetes (T2D), according to a study published online Nov. 30 in Diabetes Care.

Jin-Kui Yang, M.D., Ph.D., from Capital Medical University in Beijing, and colleagues performed a shotgun urine proteomic analysis in patients with microalbuminuria (MAU) and proliferative diabetic retinopathy (PDR; cases) and in patients with MAU and T2D for more than 10 years without any retinopathy (controls). Two hundred ten patients with T2D were followed for a median of 5.3 years in the cohort study.

The researchers found that the top two proteins with the highest difference in ratio of case to control subjects were haptoglobin and α-2-macroglobulin (8.7- and 5.7-fold, respectively; both P < 0.0001). Patients with versus those without baseline urinary haptoglobin ≥20 ng/min (haptoglobinuria) had elevated incidence of chronic renal insufficiency (CRI; hazard ratio, 3.27; P = 0.006) in the cohort study. The overall CRI rate was 3.2, 9.5, and 13.3 percent, respectively, for patients with haptoglobinuria or MAU, for those with MAU, and for those with haptoglobinuria. Patients with both MAU and haptoglobinuria had the highest rate for CRI (22.4 percent; P < 0.001).

"Urine haptoglobin, which is specific for PDR, is a novel biomarker and complement to urine albumin for predicting kidney damage in patients with T2D," the authors write.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves Kinase Inhibitor for Treatment of AML

FDA Approves Kinase Inhibitor for Treatment of AML

Midostaurin, in combination with chemotherapy, treats acute myeloid leukemia in adults

Enzyme Replacement Drug OK'd for Form of Batten Disease

Enzyme Replacement Drug OK'd for Form of Batten ...

Brineura will be used to treat children with late infantile neuronal ceroid lipofuscinosis type 2 Batten

is free, fast, and customized just for you!

Already a member?

Sign In Now »